Deferiprone reduces hemosiderin deposits in the brain of a patient with superficial siderosis.
A man with superficial siderosis showed improvement in symptoms and reduction in hemosiderin by MR imaging following treatment with deferiprone, a lipid-soluble iron chelator.
Department of Neurology, Johns Hopkins University, Baltimore, Maryland, USA. mlevy@jhmi.edu
M
M
Levy
R H
RH
Llinas
D000368:Aged; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D000077543:Deferiprone; D006485:Hemosiderin / Q000378:metabolism*; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging / Q000379:methods; D009682:Magnetic Resonance Spectroscopy / Q000379:methods; D008297:Male; D011728:Pyridones / Q000627:therapeutic use*; D012806:Siderosis / Q000188:drug therapy* / Q000378:metabolism*; D014018:Tissue Distribution; D016896:Treatment Outcome
D007502:Iron Chelating Agents; D011728:Pyridones; D000077543:Deferiprone; D006485:Hemosiderin